In summary, the study provides evidence for the rapid production of vaccine-specific antibodies, both IgA and IgG. Moreover, neutralization capacity for breastmilk was observed in all samples. This study also indicates the potential protection conferred on breastfed infants by the administration of t...
First insights into the immunogenicity of the BNT162b2 vaccine in an immunocompromised patient population have been reported as interim results from the SOAP-trial on can- cer patients: the immune response following the prime dose was low in solid cancer patients (< 40%) and very low in ...
Figure 1. Trial profile for prospective (A) and retrospective (B) cohort All participants in the prospective study were advised, both orally and in writing, about the study and provided written informed consent to participate. The entire study (prospective and retrospective parts) was approved by...
, Oxford COVID Vaccine Trial Group T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial Nat. Med., 27 (2021), pp. 270-278 CrossrefView in ScopusGoogle Scholar Flores-Alanis et al., 2021 A. Flores-Alanis, A. ...
pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b2 in patients with at least one underlying medical condition at high risk for severe COVID-19.#MEDLINE, Embase, and Cochrane databases were searched for relevant articles from January 1, 2019 to February 9,...
The phase I clinical trial of an intradermal BNT162b2 mRNA booster after the completion of a primary series of inactivated SARS-CoV-2 vaccines was previously reported by our group. Serological responses were shown together with simple cellular immunity analysis. Here, we provide more details on ef...
Immunogenicity and Reactogenicity of BNT162b2 Booster in ChAdOx1-S-Primed Participants (CombiVacS): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial. Lancet 2021, 398, 121–130. [Google Scholar] [CrossRef] van Gils, M.J.; Lavell, A.; van der Straten, K.; Appelman, ...
The clinical trial data submitted to FDA for the approval of BNT162b2 included data on eligible volunteers who were medically healthy or who had chronic conditions. Patients undergoing treatment with immunosuppressive therapy, including anti-cancer therapy, were excluded from the clinical trials [7]....
In summary, our study demonstrates that the BNT162b2 mRNA vaccine induces SARS-CoV-2-specific antibodies in HIV-1-infected patients on antiretroviral therapy, however, lower vaccine induced neutralization activity indicates a lower functionality of the humoral vaccine response in HIV-1+ patients. ...
We observed a statistically significant decrease in the number of new cancer diagnoses and in new clinical trial enrollment, as well as a change in drug administration, with less intravenous and more oral drug administration [17]. Before any explanation can be found, it is essential to define ...